Corporate Banner
Satellite Banner
Technology Networks Header
Thursday, May 17, 2012
Technology Networks
 
Register | Sign in
Home Page>Blog
  Biobanking, Bioprocessing and Biologics Blog
Scientific News
Model Requirements for Biobank Software Systems
The overview shows that the guideline successfully incorporates the best practices of international standards on biobanks, giving users a single and consistent document to review.
Mucosis Announces Positive Proof-Of-Concept Data for Mimopath® Platform in Humans
Mimopath®-based vaccines are able to produce balanced immune responses in both circulating blood and the respiratory tract.
Prosonix Demonstrates Improved Delivery and Co-localization of Respiratory Medicines
New review published in European Respiratory Disease(ERD).
Mucosis Announces Publication of Preclinical Data of Novel Influenza Vaccines
Mucosally administered Mimopath-based influenza vaccine protects against both homologous and heterologous challenge.
Insights into MRSA Epidemic
Scientists identify a gene playing a pivotal role in epidemic waves of MRSA infections in Asia.
Possible Clues Found to why HIV Vaccine Showed Modest Protection
Analysis by NIH-supported scientists may help identify requirements for HIV vaccine.
HPV Vaccine May Help Women With Cervical Conditions
Healthcare article reports how study suggests immunization can reduce their risk for cervical disease later on.
J. Craig Venter, Ph.D., Describes Biofuels, Vaccines and Foods from Made-to-Order Microbes
Scientists are using decades of knowledge garnered from sequencing or “reading” the genetic codes of thousands of living things to now start writing new volumes in the library of life.
‘Universal’ Vaccines could Finally Allow for Wide-Scale Flu Prevention
An emerging class of long-lasting flu vaccines could do more than just save people the trouble of an annual flu shot.
Analysis of Host-Cell Proteins in Biotherapeutic Proteins by Comprehensive Online Two-Dimensional Liquid Chromatography/Mass Spectrometry
This paper presents assays for identification and quantification of host-cell proteins in biotherapeutic proteins over 5 orders of magnitude in concentration.

Nice to hear it’s not just me……
06 Mar 2012

Although it has been a few years since I actually stepped foot in a lab to perform an actual, real-life experiment I still consider myself a scientist (and always will).

It is therefore incredibly frustrating when I see how some scientific news stories are reported in the media. It seems that barely a day goes by without certain British newspapers running a story about what everyday food/activity/electronic item* (*delete as appropriate) causes cancer. Having said that, I often wonder if my frustration is yet another sign that I am becoming a grumpy old man.

This excellent blog post from Martin Robbins at The Guardian makes me feel a whole lot better about myself and really highlights why scientific reporting in the media should be taken with a healthy dose of salt.

I would really like to hear your thoughts and experiences with how science is reported in the media.

Ashley
Managing Editor

Posted By: A.Board0 Comments
 

An Instrument Interfacing Business Case: Interview with Hera Group
24 Jan 2012

Written by Sergio Nasi of LABVANTAGE Solutions, Inc.

Yet, effective and streamlined interfaces between a LIMS system and analytical instruments can have a great and positive impact on the productivity and profitability of the laboratory.

We discuss this topic with Daniele Nasci, Head of the analytical laboratory of Sasso Marconi (Bologna, Italy) of Hera Group, one of the biggest Italian, multi-utility companies which provides environmental, water and energy services. Hera Group was created in 2002 from the merger of eleven public utilities companies operating in Regione Emilia Romagna. They are publicly traded on the Italian stock exchange, have a workforce of almost 7,000 employees and have impressive revenues, which exceeded 3.7 billion euros in 2010.

Q: Mr. Nasci, could you please give us a short history of the evolution of the laboratory within the Hera Group?

DN: Since the inception of the holding, the laboratory  has always been an important part of our enterprise business processes and over the years it has become a paramount business unit, playing a critical role in the control of the quality of the services provided by Hera to its customers.

Q: How many laboratory units belong to your organization and what geographical area do they cover?

DN: There are three lab units, specialized by analytical matrix and localized in the following sites:

  • Sasso Marconi (Bologna) for water and microbiology analyses
  • Forlì for solid waste, micro-pollutants and atmosphere emissions
  • Ravenna for hazardous liquid waste

The collected samples come from an area covering more than 60% of Regione Emilia Romagna and in particular the districts of Bologna, Modena, Ferrara ,Bologna, Forlì, Cesena and Rimini.

Q: For how many years have you been using a LIMS system and what are the most important benefits?

DN: We adopted a LIMS system back in 1991 when we launched the initial implementation on SQL*LIMS version 4.0.16, subsequently upgraded to newer versions, a milestone achievement which drastically boosted laboratory productivity and produced countless benefits. To name a few: a dramatic increase in speed and accuracy of the electronic processing, management and archiving of data, ease of access by our customers to the information stored in the system. Our LIMS is centralized, it serves the three laboratories and our clients can review analytical results in real-time, be notified via email in case of out-of-specs, generate and print analysis reports, etc.

Q: What were the main factors which drove the adoption of interfaces between LIMS and laboratory instruments?

DN: In the Sasso Marconi laboratory alone, we perform about 500,000 analytical tests per year. Prior to establishing the connectivity between LIMS and the instrumentation and automating the data collection procedures, 2 FTEs were assigned to manual result entry. With the adoption of instrument interfacing we were able to re-assign this staff to more productive tasks, almost eliminate the errors in the transcription of results from the instrument to the LIMS and greatly reduce the task turn-around and time. We could then deliver analytical results to our customers faster and more reliably, reduce the re-analysis rate, abate the number of complaints and increase the overall quality of our services.

Q: What are the types of instruments currently interfaced?

DN: We connected the most commonly used analytical methods such as Inductively Coupled Plasma (ICP), Gas Chromatography and Mass Spectrometry (GC-MS), Total Organic Carbon (TOC).

Q: In light of your experience ,what do you think future developments might be?

DN: We aim to implement fully bi-directional protocols in that complete worklists (including the list of samples to be analyzed and the required analytical parameters) can be transmitted to the instrument, sparing the operator from the hassle of manually specifying on the instrument’s computer the list of submitted samples and the wanted analytical determinations.

Q: Where do you see margins for improvement and how do you think LABVANTAGE can help you?

DN: I’m seeing a clear trend towards the adoption of fully computerized procedures and progressive elimination of paperwork. This trend, which is proceeding at a fast pace in other industries such as pharmaceuticals, is now gaining momentum in laboratory units of utility companies like ours. We are therefore considering with great interest the electronic laboratory notebook solution (ELN) offered by LABVANTAGE.

About LABVANTAGE

LABVANTAGE Solutions, Inc. is headquartered in Somerset, NJ, with offices around the world. We offer a comprehensive portfolio of products and solutions for the laboratory, including Laboratory Information Management Solutions (LIMS), quality electronic laboratory notebook (ELN) and business intelligence. www.labvantage.com.

Posted By: KRAT7270 Comments
 

ESBB Inaugural Conference 2011
23 Jan 2012

Written by Andrew Miles of LABVANTAGE Solutions, Inc.

Matt Rogers and I were very proud to attend the first annual meeting of ESBB (European, Middle Eastern & African Society for Biopreservation and Biobanking) held in Marseille, France from November 16th to 19th 2011. LABVANTAGE has supported this European chapter of ISBER since its inception in 2010 and is delighted to have 2 representatives on the ESBB Vendor Committee.

The organizing committee couldn’t have chosen a better venue to host this inaugural meeting. It opened in warm autumn sunshine and clear blue skies at the Pullman Palm Beach Hotel, off the shores of the Mediterranean. I have known the ESBB President, Pasquale De Blasio, for two years now, through our work with Biorep in Italy. It was great to meet him again as he personally welcomed us to the conference.

Approximately 350 delegates, from all around the world, registered for the event and enjoyed a challenging and varied agenda of lectures and presentations following the conference theme of “Identifying the challenges and opportunities for biorepositories today and in the next 5 years.” Focused sessions highlighting ethical issues, funding, biobank networks, and novel technologies, amongst other subjects, were well attended and generated much interest and lively debate amongst the audience. Having the opportunity to attend some of the lectures in person is a valuable opportunity to broaden and update our domain knowledge within the company, therefore allowing us to provide better solutions for our customers. An informal evening reception provided the ideal opportunity for delegates to catch up with old friends and colleagues and relax over a glass (or two) of wine. Matt and I took the opportunity to enjoy a leisurely dinner with one of our partners from France who was attending the meeting.

LIMS & BI by LABVANTAGE | Andy Miles ESBB 2011An extensive exhibition area was open to delegates throughout the 3 days of the conference, 36 vendors and sponsors representing a broad range of hardware and software solutions from across the Biobanking sector were present. LABVANTAGE was delighted to welcome both new prospects and existing customers to its exhibition stand during the event. As always, there was a significant amount of interest in our market-leading Bio-Bank solution. An existing customer came over to say hello and mentioned a couple of issues that needed attention. A short discussion and a phone call later, the issues were resolved. You never know what will come up during these meetings, but we are always happy to help.

For more information on ESBB and to view the full conference agenda visit www.esbb.org.

About LABVANTAGE

LABVANTAGE Solutions, Inc. is headquartered in Somerset, NJ, with offices around the world. We offer a comprehensive portfolio of products and solutions for the laboratory, including Laboratory Information Management Solutions (LIMS), quality electronic laboratory notebook (ELN) and business intelligence. www.labvantage.com.

Posted By: KRAT7270 Comments
 

Biobanking - Collaborating for Global R&D and Investment
19 May 2011

With unquestionable commercial growth opportunities, biobanks need to deliver quality samples to create value for biomarker discovery and personalised medicine. However who should implement quality control; should biobanks be self regulating or should an independent certified organisation develop a system of accreditation?

SMi's inaugural Biobanking conference is the perfect opportunity to network with the industry's leading figures and contribute to the successful future of drug discovery. Join us at the Crowne Plaza - The City, London, on the 11th - 12th July to discuss the latest developments in the biobanking arena. Take part in this brilliant forum which aims to bridge the gap between the worlds' leading academia and the pharma industry.

One of the focal points at this conference will be the impact of drug discovery on neurology disorders. Dr Rivka Ravid, Senior Scientist, Royal Dutch Academy of Sciences, Brain Bank Consultants, will use her wealth of knowledge to inform delegates of the pitfalls and practicalities in the daily practice of Brain Banks for biomedical research.

Dr Sven Kili, Global Medical Director - Cell Therapy & Regenerative Medicine, Genzyme, provides a thorough insight regarding the application of regenerative medicine. Like most strands of medical research, the value and ultimate success of regenerative medicine in tissue engineering relies heavily on the ability to maintain quality standards in a sample collection.

The forum will also look at the operational considerations within biobanking and the need for standardisation within the various networks. George Tokiwa, Associate Scientific Director at Merck will spearhead a panel-led debate regarding the most suitable system of accreditation with use of case studies to highlight best practice between biobanks.

These are just a few of the reasons why you should attend SMi's Biobanking conference. For further information please visit the website:

http://www.smi-online.co.uk/bio-banking-event63.asp

**Keep an eye on this blog, updates to follow!**

 

Posted By: awilliamson@smi-online.co.uk4 Comments
 
<< 1 2 >>
Showing Results 1 - 4 of 5
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Get The App
Go to LabTube.tv
Go to ePosters.net